Interactive modeling and evaluation of tumor growth.

J Digit Imaging

Instituto de Informática, Universidade Federal do Rio Grande do Sul, Caixa Postal 15064, 91501-970, Porto Alegre, RS, Brazil.

Published: December 2010

This paper addresses the need to quantify tumor growth and detect changes as this information is relevant to manage the patient treatment and to aid biotechnological efforts to cure cancer (Silva et al. 2008). An interactive tumor segmentation technique is used to recover the shape and size of tumors without imposing shape constraints. This segmentation algorithm provides good convergence, is robust to the initialization conditions, and requires simple and intuitive user interactions. A parametric approach to model tumor growth analytically is proposed in this paper. The preliminary experimental results are encouraging. The segmentation method is shown to be robust and simple to use, even in situations where the tumor boundary definition is challenging. Also, the experiments indicate that the proposed model potentially can be used to extrapolate the available data and help predict the tumor size (assuming unconstrained growth). Additionally, the proposed method potentially can provide a quantitative reference to compare the tumor shrinkage rate in cancer treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046685PMC
http://dx.doi.org/10.1007/s10278-009-9234-4DOI Listing

Publication Analysis

Top Keywords

tumor growth
12
tumor
7
interactive modeling
4
modeling evaluation
4
evaluation tumor
4
growth
4
growth paper
4
paper addresses
4
addresses quantify
4
quantify tumor
4

Similar Publications

Introduction: Hematologic malignancies, originating from uncontrolled growth of hematopoietic and lymphoid tissues, constitute 6.5% of all cancers worldwide. Various risk factors including genetic disorders and single nucleotide polymorphisms play a role in the pathogenesis of hematologic malignancies.

View Article and Find Full Text PDF

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Cancer Commun (Lond)

January 2025

Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.

Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.

View Article and Find Full Text PDF

X-ray Responsive Antioxidant Drug-Free Hydrogel for Treatment of Radiation Skin Injury.

ACS Appl Mater Interfaces

January 2025

State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, P. R. China.

Radiotherapy (RT) is widely applied in tumor therapy, but inevitable side effects, especially for skin radiation injury, are still a fatal problem and life-threatening challenge for tumor patients. The main components of topical radiation protection preparations currently available on the market are antioxidants, such as SOD, which are limited by their unstable activity and short duration of action, making it difficult to achieve the effects of radiation protection and skin radiation damage treatment. Therefore, we designed a drug-free antioxidant hydrogel patch with encapsulated bioactive epidermal growth factor (EGF) for the treatment of radiation skin injury.

View Article and Find Full Text PDF

Quiescent pancreatic stellate cells (PSCs) represent only a very low proportion of the pancreatic tissue, but their activation leads to stroma remodeling and fibrosis associated with pathologies such as chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC). PSC activation can be induced by various stresses, including acidosis, growth factors (PDGF, TGFβ), hypoxia, high pressure, or intercellular communication with pancreatic cancer cells. Activated PSC targeting represents a promising therapeutic strategy, but little is known regarding the molecular mechanisms underlying the activation of PSCs.

View Article and Find Full Text PDF

Background/aims: Bruise is the extravasation of blood that may be mild or severe. Bone marrow mesenchymal stem cells (BM-MSCs) are one of the most promising cells used in regenerative medicine for treating many disorders. We aimed to evaluate the efficiency of BM-MSCs in treating cutaneous bruises.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!